LA JOLLA, Calif.--(BUSINESS WIRE)-- DermTech, Inc., the global leader in non-invasive molecular dermatology, announced today the appointment of Daniel M. Siegel, MD, to its Scientific Advisory Board. Dr. Siegel is a Clinical Professor of Dermatology and former Director of the Procedural Dermatology Fellowship at SUNY Downstate. He has served as a president of the AAD (2012) and is a past member of both the Academy’s board of directors and Coding and Reimbursement Task Force. He is a diplomate of the American Board of Dermatology and the American Board of Laser Surgery and is a fellow of the American Society for Dermatologic Surgery (ASDS), the American Academy of Dermatology (AAD), the American College of Mohs Surgery and the American Society of Mohs Surgery.
Dr. Siegel earned his medical degree from Albany Medical College in Albany, N.Y. He completed his residency in dermatology at the University of Texas Health Sciences Center at Dallas and his fellowship at the Baylor College of Medicine in Houston. Dr. Siegel also earned a Master of Science degree in management and policy from Stony Brook University, Stony Brook, N.Y.
Dr. Siegel has received many honors and awards including the 2013 American Skin Association Public Policy & Medical Education Award and the Academy of Dermatology Presidential Citation, which he received in 2000, 2006, 2007, 2009, and 2010. He has published more than 100 articles and book chapters in major medical journals and textbooks.
DermTech is the global leader in molecular dermatology, bringing precision medicine to the diagnosis and treatment of skin disease. We market and develop products that facilitate the early detection of skin cancers, assess inflammatory diseases, and customize drug treatments. DermTech analyzes skin biopsy samples collected non-invasively using an adhesive patch rather than a scalpel. Our mission is to transform dermatology by delivering highly accurate and objective information to the clinician to improve care and reduce costs and to pharma partners to support the development of targeted therapeutics. For additional information visit: dermtech.com.
View source version on businesswire.com: http://www.businesswire.com/news/home/20171023005482/en/
Sarah Dion, MBA
VP, Sales and Marketing
Source: DermTech, Inc.